Ashling Wahner

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

October 23rd 2025

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

Dr Xie on the Rationale for Investigating HS-20093 in Relapsed/Refractory Sarcomas

October 23rd 2025

Lu Xie, MD, discusses the scientific rationale and clinical development strategy for HS-20093 in the phase 2 ARTEMIS-002 trial.

FDA Approves Belantamab Mafodotin Plus Bortezomib and Dexamethasone for R/R Multiple Myeloma

October 23rd 2025

Vopimetostat Demonstrates Early Evidence of Efficacy in MTAP-Deleted Solid Tumors

October 23rd 2025

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC

October 23rd 2025

The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.

FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC

October 23rd 2025

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.

Adjuvant Cemiplimab Approval Redefines Management of High-Risk CSCC

October 23rd 2025

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.

Dr Tarantino on De-Escalated THP With/Without Carboplatin in HER2+ Breast Cancer

October 23rd 2025

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Dr Visco on the Efficacy and Safety of Venetoclax Plus RBAC in High-Risk MCL

October 23rd 2025

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

Dr Randall on the Potential Role of Ultrasound in Soft Tissue Sarcoma Surveillance

October 23rd 2025

R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

October 22nd 2025

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

CAR2219 CAR T-Cell Therapy Yields Responses and a Manageable Safety Profile in R/R LBCL

October 21st 2025

CAR2219 induced high response rates in relapsed/refractory LBCL, and the role of post-infusion maintenance therapy is worthy of further study.

Liso-Cel Data Confirm Durable Efficacy and Confer Broad Use in R/R LBCL

October 21st 2025

Taylor Brooks, MD, discusses data that supported the FDA approvals of liso-cel across LBCL treatment settings and details of the agent’s toxicity profile.

Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

October 21st 2025

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Dr Mouhieddine on Clinical Implications of Ferritin and ALC as Biomarkers in Myeloma

October 21st 2025

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

Dr Lee on the Optimal Patient Population to Receive Proton Therapy for Advanced NSCLC

October 21st 2025

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards

October 21st 2025

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

Metastatic Breast Cancer 2025 UPDATE

October 20th 2025

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer

October 20th 2025

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.